Approach

Summary

Licensing status

Publication and contact information

Drug platforms

Immunosupression regimen to prevent immunotoxin neutralization

A small clinical study suggests combining the immunosuppressive drugs pentostatin and cyclophosphamide could prevent neutralizing antibodies against immunotoxin treatment in cancer. In 11 patients with mesothelioma, combining the 2 drugs with the immunotoxin SS1P, which contains a portion of a bacterial exotoxin, delayed the formation of neutralizing antibodies against the toxin. In 10 evaluable patients, 3 had durable partial responses, 3 had stable disease and 4 had progressive disease. Next steps include planning additional clinical trials.

SciBX 6(46); doi:10.1038/scibx.2013.1336
Published online Dec. 5, 2013

Patent and licensing status undisclosed

Hassan, R. et al. Sci. Transl. Med.; published online Oct. 23, 2013;
doi:10.1126/scitranslmed.3006941
Contact: Raffit Hassan, National Institutes of Health (NIH),
Bethesda, Md.
e-mail:

hassanr@mail.nih.gov